The clinical symptoms of catheter-related bloodstream infection (CRBSI) can include fever, septic shock, and severe sepsis. Blood cultures showing Staph. aureus and Candida species may suggest catheter-related infection. While largely preventable, catheter-related bloodstream infections are not uncommon and are not necessarily caused by inexperience. In fact, catheter-related infections rank among the three leading causes of hospital-acquired infections. The infection is estimated to affect four to 17 percent of hospital-bound patients. It is associated with a high mortality rate and a case fatality rate of 14%. Catheter-related bloodstream infections account for 19% of all hospital-acquired deaths.
Request PDF Research Report Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/4805
Furthermore, as per the study published in National Center for Biotechnology Information (NCBI) regarding catheter-related bloodstream infection indicates that globally, the number of incidences of catheter related bloodstream infection is estimated to be four million patients.
Global Catheter Related Blood Stream Infection Market – Dynamics
Furthermore, WHO study indicates that most of the countries lack in the surveillance systems for infections related to health care and these reasons often result in struggle with the complexity and lack of standardized criteria for diagnosing the infections. Serious effects are associated with inaccurate diagnosis, results complication or lead to increase in mortality and morbidity. Due to which it is necessary to diagnose catheter related bloodstream infection accurately.
Likewise, the market players are conducting research and development activities for the innovation of better products for the prevention of catheter related blood stream infection. This is expected to increase the growth of the global catheter related bloodstream infection market over the forecast period. For instance, on August 4, 2021, Citius Pharmaceuticals, a biopharmaceutical company which focused on development and commercialization of products based on critical care. Company announced that, Mino-Lok it is an antibiotic lock solution, which is used for treatment of patients with catheter related bloodstream infection. As per phase 2b trial results Mino lok demonstrated 100 % efficacy rate. And multicenter phase 3 clinical trial of Mino-Lok is currently underway. Mini-Lok by Citius pharmaceuticals has potential to be the first and only Food and Drug Administration (FDA) approved product to be used for infected CVCs and the company plans to file a new drug application (NDA) in 2022.
Owing to the growing cases in health care associated infections in the U.S., the government offers reimbursement policy to the patients. For instance, as per programs in centers for Medicare and Medicaid services (CMS), the HAC Reduction Program provide services for catheter related bloodstream infection. This program encourage hospitals to provide safety assurance to infected patients. The Medicare provided through this program is US$ 9,504 Mn.
Global Catheter Related Blood Stream Infection Market – Regional Insights
Among regions, North America extended enormous share of catheter related bloodstream infection in global market during the forecast period, due to the infrastructure establishment in health care. For instance, In the United States, an estimated 250,000 bloodstream infection occur annually, and most are related to the presence of intravascular devices. The rate of bloodstream infection for intensive care units (ICU) is estimated to be 0.8 per 1000 days. The Hospital Acquired Condition (HAC) reduction program by the U.S. government encourages hospitals for patients’ safety. Moreover, as per National Health Expenditures 2019, in the U.S. available on CMS indicates that the upcoming National health spending will increase the annual growth rate by 5.4 % for 2019-2028.
Furthermore, Europe region is projected to anticipate the second largest market after North America from 2020 to 2030. For instance, according to the report published by the European Center for Disease Prevention and Control (ECDC), the prevalence of CVC in Europe is approximately 7.1%. The ECDC center estimates that every year in Europe the number of Catheter related bloodstream infection patients is approximately 4,13, 000 from overall number of patients associated with health care infections.
Get PDF Sample Copy of Report (Including Full TOC, List of Tables & Figures, Chart) @ https://www.coherentmarketinsights.com/insight/request-sample/4805
Global Catheter Related Blood Stream Infection Market – Taxonomy
By Drug Class:
- Non-antibiotic
- Anti-infective
- Antimicrobial
By Pathogenesis:
- Contaminated Catheter Hub
- Contaminated Infusate
- Skin Insertion
- Hematogenous
By Source of Infection/Micro-organisms:
- Aureus
- aeruginsa
- CONS
- Baumanii
- coli
- pnemoniae
- Candida sp.
By Route of Administration:
- Oral
- Intravenous
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Global Catheter Related Blood Stream Infection Market – Competitive landscape
Key players involved in the global catheter related blood stream infection include Citius Pharmaceuticals, CorMedix, Geistlich Pharma, TauroPharm GmbH, Fresenius Medical Care, AstraZeneca Pharma India Ltd., Glenmark Pharmaceuticals Ltd., Xellia Pharmaceuticals Ltd., and Pfizer.
Buy This Report with Flat USD 2000 Off @ https://www.coherentmarketinsights.com/promo/buynow/4805
Table of Content
Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Catheter Related Blood Stream Infection Market Size Analysis from 2022 to 2028
11.6 COVID-19 Outbreak: Catheter Related Blood Stream Infection Industry Impact
Chapter 2 Global Catheter Related Blood Stream Infection Competition by Types, Applications, and Top Regions and Countries
2.1 Global Catheter Related Blood Stream Infection (Volume and Value) by Type
2.3 Global Catheter Related Blood Stream Infection (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Catheter Related Blood Stream Infection Sales, Consumption, Export, Import by Regions (2017-2022)
Chapter 5 North America Catheter Related Blood Stream Infection Market Analysis
Chapter 6 East Asia Catheter Related Blood Stream Infection Market Analysis
Chapter 7 Europe Catheter Related Blood Stream Infection Market Analysis
Chapter 8 South Asia Catheter Related Blood Stream Infection Market Analysis
Chapter 9 Southeast Asia Catheter Related Blood Stream Infection Market Analysis
Chapter 10 Middle East Catheter Related Blood Stream Infection Market Analysis
Chapter 11 Africa Catheter Related Blood Stream Infection Market Analysis
Chapter 12 Oceania Catheter Related Blood Stream Infection Market Analysis
Chapter 13 South America Catheter Related Blood Stream Infection Market Analysis
Chapter 14 Company Profiles and Key Figures in Catheter Related Blood Stream Infection Business
Chapter 15 Global Catheter Related Blood Stream Infection Market Forecast (2022-2028)
Chapter 16 Conclusions
Research Methodology
About Us:
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837